SCHEMBL4454512

SCHEMBL4454512

Nc1nn(-c2cccc(F)c2)cc1NC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.48
ADORA2A P29274 1/20 0.48
HDAC1 Q13547 5/20 0.45
HDAC2 Q92769 3/20 0.45
KDM4E B2RXH2 4/20 0.42
MAPT P10636 3/20 0.42
KEAP1 Q14145 1/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
NOTUM Q6P988 2/20 0.40
MAPK14 Q16539 1/20 0.40
NPC1 O15118 1/20 0.39
RIPK1 Q13546 1/20 0.39
MAPK1 P28482 1/20 0.39
LMNA P02545 2/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4455282 0.85 ADORA3 (0.49) ADORA3ADORA2AHDAC1HDAC2KDM4E
SCHEMBL3999180 0.85 PARP1 (0.48) ADORA3ADORA2AHDAC1HDAC2KDM4E
SCHEMBL2887260 0.84 HDAC1 (0.57) ADORA3ADORA2AHDAC1HDAC2KDM4E
SCHEMBL14312644 0.84 ADORA3 (0.48) ADORA3KDM4EMAPTKMT2AMEN1
SCHEMBL4454941 0.83 HDAC1 (0.58) HDAC1HDAC2KDM4EMAPTKMT2A
SCHEMBL8241599 0.82 GRM5 (0.42) ADORA3ADORA2AHDAC1HDAC2KEAP1
SCHEMBL14312276 0.82 ADORA1 (0.50) ADORA3ADORA2AHDAC1HDAC2KDM4E
SCHEMBL14312436 0.79 KDM4E (0.46) HDAC1HDAC2KDM4EMAPTKMT2A
SCHEMBL14312439 0.76 LMNA (0.49) ADORA3ADORA2AHDAC1HDAC2KDM4E
SCHEMBL14312424 0.76 HDAC1 (0.41) ADORA3ADORA2AHDAC1HDAC2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1945617-B1 HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS MERCK SHARP & DOHME (US) 2012-12-26 EP disclosed
US-20090291965-A1 Histone Deacetylase Inhibitors With Aryl-Pyrazolyl-Motifs MERCK SHARP & DOHME LLC 2009-11-26 US disclosed
EP-1945617-A2 HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS Merck & Co., Inc. (US) 2008-07-23 EP disclosed
WO-2007055941-A2 HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS MERCK & CO., INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291965-A1 Histone Deacetylase Inhibitors With Aryl-Pyrazolyl-Motifs HDAC1, HDAC3, HDAC5 ADORA3 4119/4885ADORA2A 4371/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.